Navigation Links
Diabetes drug supported by Mexican Diabetes Federation

VANCOUVER, June 21, 2007 /PRNewswire-FirstCall/ - Biotech Holdings reports that the Mexican Diabetes Federation has given Biotech's "Sucanon" diabetes drug its support in an overview of diabetic drugs published in the May-June 2007 issue of Diabetes Hoy, the Diabetic Federation's scientific and medical magazine for doctors and other health professionals.

The overview of diabetic drugs, written by Dr. Roberto Cepeda Gonzalez, Medical Director of the Specialized Center for Diabetes, in Mexico City, notes that Sucanon falls in a category of diabetic drugs known as "insulin sensitizers" for their action in making the body's cells more sensitive to circulating insulin. The review (see Endorsements at http://www.sucanonhealth.com/section.asp?pageid=4107) notes that the most widely used insulin sensitizers belong to a family of drugs known as thiazolidinediones or glitazones.

The glitazone drugs, the review notes, have a history of problems in contrast with Sucanon which, clinical studies have indicated, is very safe. The review notes that Sucanon does not have any of the hepatotoxicity or liver-damage risks of the glitazone drugs. The first glitazone, troglitazone was approved in 1998 but was withdrawn shortly thereafter. Two additional glitazones - rosiglitazone and pioglitazone - have recently been targeted with a "black box" warning by the U.S. FDA due to concerns related to cardiac risk when taking these drugs (see http://www.msnbc.msn.com/id/19090626/).

The review in Diabetes Hoy also notes that another widely used Type II Diabetes medication, metformin, presents risks for patients with compromised kidney function, frequently a symptom of Type II Diabetes.

Sucanon, which received regulatory approval in Mexico in 2004, is widely sold
'"/>




Page: 1 2 3

Related medicine technology :

1. Diagnosing Diabetes: Immediate HbA1c Results Improve Glycemic Control
2. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
3. Data Demonstrated Saxagliptin Added to Metformin Improved Glycemic Control in Subjects with Type 2 Diabetes Compared to Metformin Alone
4. Data Demonstrated Saxagliptin Added to Metformin Improved Glycemic Control in Subjects with Type 2 Diabetes Compared to Metformin Alone
5. An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes
6. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
7. New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes Using Self-Adjusted Dosing Starting With Once-Daily Insulin Treatment Levemir
8. First Phase II Short-Term Study on Dapagliflozin Shows Results on Safety, Tolerability and Glycemic Markers in Subjects With Type 2 Diabetes
9. Lipitor Reduced the Risk of Coronary Events by Half and Stroke by Nearly One-Third in High-Risk Patients with Type 2 Diabetes Who Experienced a Recent Stroke
10. Sangamo BioSciences Announces Presentation of Phase 1 ZFP Therapeutic Data at American Diabetes Association Meeting
11. Phase IIIb Clinical Data Validate the Overall and Cardiovascular Safety Profile of Cycloset (A Quick Release Formulation of Bromocriptine Mesylate) in Patients with Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Diabetes drug supported Mexican Diabetes Federation
(Date:1/15/2014)... YORK , Jan. 15, 2014 ... report is available in its catalogue: ... for Advanced Drug Delivery Systems -- Focus ... STUDY OBJECTIVES ...
(Date:1/15/2014)... , Jan. 15, 2014  Zafgen, Inc., a ... needs of severely obese patients, today announced initial ... a selective inhibitor of methionine aminopeptidase 2 (MetAP2), ... form of genetic obesity.  These results showed improvements ...
(Date:1/14/2014)... 2014 HeartWare International, Inc . (NASDAQ: ... miniaturized circulatory support technologies that are revolutionizing the treatment ... revenues for the fourth quarter of 2013 will be ... approximately $208 million. "Our full-year revenue growth ...
Breaking Medicine Technology:Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4
... Both Shape and Volumetric Evaluation of ... Three dimensional visualization,of the right ventricle provides important ... patients with tetralogy of,Fallot (TOF), according to a paper ... 1, 107-113)., TOF is a disease that impacts ...
... April 8, 2008 ,Anesiva, Inc. (Nasdaq: ANSV ... trial evaluating Adlea(TM), its long-acting, non-opioid analgesic,drug candidate, ... In September 2007, Anesiva initiated a multicenter, ... safety and,efficacy of a single 5 or 15 ...
Cached Medicine Technology:Three Dimensional Visualization of Right Ventricle Provides Important Information for Treatment of Patients with Tetralogy of Fallot, According to a Study in The American Journal of Cardiology 2Three Dimensional Visualization of Right Ventricle Provides Important Information for Treatment of Patients with Tetralogy of Fallot, According to a Study in The American Journal of Cardiology 3Anesiva Announces Pivotal Phase 3 Clinical Trial of Adlea(TM) for Reducing Post-Surgical Pain Following Total Knee Replacement 2Anesiva Announces Pivotal Phase 3 Clinical Trial of Adlea(TM) for Reducing Post-Surgical Pain Following Total Knee Replacement 3Anesiva Announces Pivotal Phase 3 Clinical Trial of Adlea(TM) for Reducing Post-Surgical Pain Following Total Knee Replacement 4
(Date:4/17/2014)... a study published today in PLOS Pathogens , ... malaria is common can mount an immune response to ... avoid repeated bouts of high fever and illness and ... bloodstream. The findings may help researchers develop future interventions ... malaria parasite. , Each year, approximately 200 million cases ...
(Date:4/17/2014)... published in the April issue of Immunity , ... for Medical Research, says it,s time to take a ... treating sepsis, which kills millions worldwide every year, ... molecules released into the bloodstream to fight an injury ... necessary for maintaining good health without inflammation, wounds ...
(Date:4/17/2014)... Il. (April 17, 2014) Doctors who treat ... called lymphangioleiomyomatosis (LAM) can face an agonizing treatment ... of the disease and help relieve shortness of ... transplants, and sirolimus can cause potentially fatal complications ... pulmonologist Dr. Daniel Dilling, medical director of Loyola ...
(Date:4/17/2014)... Irvine, Calif., April 17, 2014 By discovering a ... immediately after a stroke, researchers at UC Irvine and ... therapies that may limit or prevent stroke-induced brain damage. ... the fourth-leading cause of death and primary reason for ... damaged in a stroke and lets blood-borne material into ...
(Date:4/17/2014)... potential to ward off depression among retirees, particularly among ... in The Journals of Gerontology, Series B: ... article " Internet Use and Depression Among Retired Older ... the authors report that Internet use reduced the probability ... study sample. , Late-life depression affects between 5 ...
Breaking Medicine News(10 mins):Health News:Study sheds light on how the immune system protects children from malaria 2Health News:Feinstein Institute researcher publishes new perspective on sepsis 2Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3Health News:Study IDs new cause of brain bleeding immediately after stroke 2Health News:Internet use may cut retirees' depression 2
... significantly restrict,abortion, WASHINGTON, Oct. 14 A new ... Court handed down its decision,in Roe v. Wade, public ... entire pregnancy stands at just 8%. The poll was,conducted ... Institute of,Public Opinion between September 24 and October 3, ...
... quality ratings company, today announced that it expects total revenue for ... million. This represents an increase of 23% compared with the third ... ... Wire EON) October 14, 2008 -- HealthGrades also announced that ...
... of Popular Boot Camp-Style ... La Crosse, SAN DIEGO, Oct. 14 The American ... of the largest,fitness certification, education and training organizations in the ... the,University of Wisconsin, La Crosse through its exercise and health ...
... Oct. 14 The economy is in turmoil. The,stock market ... and jobs are disappearing. Headlines scream out to us and ... become only a dream that cannot,be turned into reality. We ... to be forthcoming. We are drowning in their silence,and a ...
... Billion Increased 6.4% Versus a Year Ago; EPS was ... Increased 10.4%*, NEW BRUNSWICK, N.J., Oct. 14 ... the third quarter of,2008, an increase of 6.4% as ... 3.3% and the positive impact of currency was 3.1%.,Domestic ...
... N.C., Oct. 14 Senator McCain believes it to,be ... believe,that healthcare reform is a high priority, they disagree ... they know which plan physicians,support? A new study from ... designed to assess attitudes on universal healthcare as,it relates ...
Cached Medicine News:Health News:Nationwide Poll Shows 84% of Americans Favor Significant Restrictions on Abortion 2Health News: HealthGrades Expects Third Quarter Revenue of Approximately $10 Million : Full-Year 2008 Ratings and Advisory Revenue to Be $39 Million to $40 Million Company Provides Update on Stock Repurchase Program 2Health News: HealthGrades Expects Third Quarter Revenue of Approximately $10 Million : Full-Year 2008 Ratings and Advisory Revenue to Be $39 Million to $40 Million Company Provides Update on Stock Repurchase Program 3Health News:American Council on Exercise (ACE) Studies Impact of Boot Camp-Style Workouts 2Health News:Exercise Can Help You Cope with Financial Stress and Heal Emotional Pain, Says Acclaimed Author and Psychotherapist 2Health News:Johnson & Johnson Reports 2008 Third-Quarter Results: 2Health News:Johnson & Johnson Reports 2008 Third-Quarter Results: 3Health News:Johnson & Johnson Reports 2008 Third-Quarter Results: 4Health News:Johnson & Johnson Reports 2008 Third-Quarter Results: 5Health News:Johnson & Johnson Reports 2008 Third-Quarter Results: 6Health News:Johnson & Johnson Reports 2008 Third-Quarter Results: 7Health News:Johnson & Johnson Reports 2008 Third-Quarter Results: 8Health News:Johnson & Johnson Reports 2008 Third-Quarter Results: 9Health News:Johnson & Johnson Reports 2008 Third-Quarter Results: 10Health News:Johnson & Johnson Reports 2008 Third-Quarter Results: 11Health News:Johnson & Johnson Reports 2008 Third-Quarter Results: 12Health News:Johnson & Johnson Reports 2008 Third-Quarter Results: 13Health News:Johnson & Johnson Reports 2008 Third-Quarter Results: 14Health News:Johnson & Johnson Reports 2008 Third-Quarter Results: 15Health News:Johnson & Johnson Reports 2008 Third-Quarter Results: 16Health News:Johnson & Johnson Reports 2008 Third-Quarter Results: 17Health News:Johnson & Johnson Reports 2008 Third-Quarter Results: 18Health News:Johnson & Johnson Reports 2008 Third-Quarter Results: 19Health News:Johnson & Johnson Reports 2008 Third-Quarter Results: 20Health News:Johnson & Johnson Reports 2008 Third-Quarter Results: 21Health News:The Public Knows the Candidates' Views on Healthcare Reform, But Do the Candidates Know What Healthcare Professionals Think? 2
... Four 62 mirrors ... the angle with little ... flange is convenient for ... fissures. Anterior holding ring ...
Small size gonio lens with one 62 mirror. Compact knurled ring simplifies 360 viewing of the anterior chamber angle....
Mcintyre straight lachrymal cannula, closed end, two side ports at 0.3 mm, straight shaft....
McIntyre lacrimal cannula, dual 0.3 mm side ports, straight....
Medicine Products: